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Abstract
Background:  Retinoic acid suppresses cell growth and promotes cell differentiation, and
pharmacological retinoic acid receptor (RAR) activation is anti-tumorigenic. This begs the question
of whether chronic physiological RAR activation by endogenous retinoids is likewise anti-
tumorigenic.
Results: To address this question, we generated transgenic mice in which expression of a ligand
binding defective dominant negative RARα (RARαG303E) was under the control of the mouse
mammary tumor virus (MMTV) promoter. The transgene was expressed in the lymphoid
compartment and in the mammary epithelium. Observation of aging mice revealed that transgenic
mice, unlike their wild type littermates, developed B cell lymphomas at high penetrance, with a
median latency of 40 weeks. MMTV-RARαG303E lymphomas were high grade Pax-5+, surface H+L
Ig negative, CD69+ and BCL6- and cytologically and phenotypically resembled human adult high
grade (Burkitt's or lymphoblastic) lymphomas. We postulated that mammary tumors might arise
after a long latency period as seen in other transgenic models of breast cancer. We tested this idea
by transplanting transgenic epithelium into the cleared fat pads of wild type hosts, thus bypassing
lymphomagenesis. At 17 months post-transplantation, a metastatic mammary adenocarcinoma
developed in one of four transplanted glands whereas no tumors developed in sixteen of sixteen
endogenous glands with wild type epithelium.
Conclusion: These findings suggest that physiological RAR activity may normally suppress B
lymphocyte and mammary epithelial cell growth and that global RAR inactivation is sufficient to
initiate a stochastic process of tumor development requiring multiple transforming events. Our
work makes available to the research community a new animal resource that should prove useful
as an experimental model of aggressive sporadic lymphoma in immunologically uncompromised
hosts. We anticipate that it may also prove useful as a model of breast cancer.
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Background
Most of the biologic effects of vitamin A are mediated by
all-trans retinoic acid (RA) receptors (RARs) encoded by
three genes, RARα, β and γ, each of which give rise to mul-
tiple receptor isoforms. RARs regulate gene transcription
upon heterodimerization with retinoid X (9-cis RA) recep-
tors (RXRs). RARs and RXRs are members of the super-
family of ligand-dependent transcription factors. In the
absence of ligand, RXR-RAR represses gene transcription
by recruiting corepressors; upon ligand binding, corepres-
sors are displaced and coactivators recruited, resulting in
activation of gene transcription [1,2].
RXR-RAR activation regulates cell proliferation, apoptosis,
and differentiation, events that figure prominently in can-
cer [3-8]. Pharmacological RXR-RAR activation prevents
or slows down tumor formation in rodent models of
breast cancer [9,10]. We wondered whether chronic phys-
iological RAR activation by endogenous retinoids might
exert a qualitatively similar effect. In other words, we won-
dered whether the anti-cancer effect of pharmacological
retinoid doses might represent an enhancement of chron-
ically ongoing, physiological RAR effects. We hypothe-
sized that this might be the case and thus that inhibition
of physiological RAR activation might prompt tumor for-
mation. Studies showing that the cellular retinol-binding
protein I and RARβ2 are frequently epigenetically silenced
in cancer lent indirect support to our hypothesis [11-18].
More pertinent support came from studies showing that
RARα antisense [19] and cellular RA-binding protein I
[20] overexpression induced tumor formation in mice.
Finally, the leukemogenic effect of the t(15;17) transloca-
tion that juxtaposes the promyelocytic leukemia and
RARα genes, resulting in inhibition of the transactivation
function of RARα [21], also encouraged us to pursue our
hypothesis.
Because both RARα1 and RARβ2 have been implicated in
growth suppression [22,23], we considered studying
RARα1/RARβ2 double null mice; however, these die
shortly after birth [24], precluding this approach. We
therefore addressed our hypothesis using a dominant neg-
ative RAR transgenic approach [25]. RARα bearing a
G303E point mutation in the ligand binding domain
(RARαG303E) binds ligand poorly but retains the ability
to heterodimerize with RXR; when transfected into RA-
sensitive cells, RARαG303E inhibited the transcriptional
activity of endogenous RAR by nearly 100% at physiolog-
ical RA concentrations (1–10 nM) [26]. Moreover, 100-
fold greater concentrations of RA were required for RARα
activation of a reporter gene when RARαG303E and RARα
were expressed at a ~1:1 molar ratio [26]. These data and
the potent in vivo biological effects of RARαG303E
[27,28] led us to choose it as the dominant negative RAR
for this study.
Results
RARαG303E transgenic mice
We generated transgenic mice in which the mouse mam-
mary tumor virus (MMTV) long terminal repeat (LTR)
drives the expression of the N-terminally HA-tagged
RARαG303E dominant negative mutant developed by
Saitou et al. [26] (Fig. 1A). The MMTV-LTR has been
widely used to target transgene expression to the mam-
mary epithelium and was chosen in this study because of
our particular interest in breast cancer. However, the
MMTV-LTR is also known to target transgenes to lym-
phocytes [29-31]. Four female founder mice (#s 17, 24, 6,
39) were obtained as determined by Southern blotting
(Fig. 1B shows data for founder 17) or PCR. A hemizygous
line was successfully established from founder 17 and
maintained over eight generations. The data herein
Tissue transgene expression Figure 1
Tissue transgene expression. (A) Sketch showing the 
main features of the transgene construct. (B) Southern blot 
analysis showing the relative amounts of transgene DNA rel-
ative to WT RARα DNA in founder 17. Empty lanes corre-
spond to mice that did not integrate the transgene. (C) RT-
PCR analysis showing transgene expression in the spleen and 
mammary gland of a young, disease-free line 17 TG female 
(liver as negative control). Signal detected when the reverse-
transcription step was omitted (-RT) is due to contaminating 
DNA (see Fig. 2 for DNAse I treatment control).Molecular Cancer 2006, 5:12 http://www.molecular-cancer.com/content/5/1/12
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derived from the study of this line and to a lesser extent
founder 24 (see Methods for information on founders 6
and 39). We evaluated transgene expression by RT-PCR in
mammary tissue, spleen and liver from a transgenic
female, taking advantage of the transgene's HA tag to dis-
tinguish it from endogenous RARα. Expression was read-
ily detected in both the mammary gland and the spleen
but not the liver (Fig. 1C), consistent with previous expe-
rience as related above.
Tumor formation
Based on the transgene expression pattern, we hypothe-
sized that MMTV-RARαG303E mice might be susceptible
to lymphoma and/or mammary tumor development.
Adult transgenic (TG) female mice (line 17) and wild type
(WT) female littermates were examined over time for evi-
dence of tumor development. We found that TG mice
developed node-based tumors at high penetrance, with a
median latency of 40 weeks; no tumors arose among WT
littermates (Fig. 2A). Histological and molecular analyses
established that the tumors were B cell lymphomas
(below) and RT-PCR analysis demonstrated that they
expressed the transgene (Fig. 2B). Founder 24 developed
B cell lymphoma at 33 weeks of age. Thus, lymphoma
development was associated with MMTV-RARαG303E
expression and occurred in two independent TG lines
against a tumor-free background in WT mice, suggesting
that it is a product of transgene expression rather than
insertional mutagenesis. Lymphomagenesis in line 17 was
a reproducible feature over 8 generations. Notably, we did
not detect mammary tumors, possibly because the latency
period for their formation is longer (see below).
Molecular analysis of tumors
All lymphomas were high grade B cell lymphomas, pre-
dominantly node-based, and characterized by organ infil-
tration in liver, spinal cord, and muscle. The morphology
ranged from immature blasts with small nucleolus, fine
chromatin, mild or moderate nuclear pleomorphism,
scanty cytoplasm, abundant mitotic activity (Fig. 3, panel
A) to slightly larger cells with vesicular chromatin, prom-
inent nucleolus, mild nuclear pleomorphism and often
starry sky appearance, this latter morphology consistent
with Burkitt's lymphoma [32]. Consistently, lymphomas
were Pax5+, B220+, CD43+, AA41+, CD69+ and negative
for surface heavy or light chain immunoglobulins, CD5,
CD4, CD8, CD23, CD21, BCL6 (Fig. 3, panels B and C,
and Fig. 4). In five typical cases, tumor cells were negative
for c-MYC, BCL2, OCT-2, p53 and IRF4. In three typical
cases tested, tumor cells were negative for MCL-1. The
lymphomas that arose in founder 24 were histologically
indistinguishable from typical line 17 lymphomas and
like these were Pax5+ and BCL6- by immunostaining.
One case had a biphasic cellular infiltrate in the spleen,
composed of immature lymphoblasts with fine chroma-
tin and monocytoid immature elements, in adjacent sep-
arate areas (Fig. 3, panel D). This tumor was composed of
immature lymphoma/leukemia (Pax5+, TdT+, CD3-,
Mac2-) and myelomonocytic leukemia (Pax5-, TdT-,
CD3-, Mac2+) (Fig. 3, panels E and F) [33]. On secondary
transplant, only the B cell component grew.
Lymphoid system in young transgenic mice is normal
Bone marrow, spleen, thymus and peritoneal cells from 3
TG and 3 WT littermates, age 17 weeks, were analyzed for
Tumor incidence and transgene expression Figure 2
Tumor incidence and transgene expression. (A) Kap-
lan-Meier plot showing the percentage of tumor-free animals 
as a function of post-natal age in weeks for line 17 TG and 
WT females.(B) Top, tumor transgene expression (RT-PCR 
using Trizol-isolated RNA). Data is shown for two tumors 
and spleen of one lymphomatous TG female (M, markers). 
The relatively low -RT signal is due to contaminating DNA as 
demonstrated by loss of the signal after DNAse I treatment 
(last two lanes). Bottom, transgene expression in a tumor 
from another TG female, using RNA isolated with the less 
stringent Purescript protocol. The strong -RT signal is lost 
upon DNAse I treatment.Molecular Cancer 2006, 5:12 http://www.molecular-cancer.com/content/5/1/12
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immature (B220dim CD43+) and mature (B220+ CD43-
) bone marrow (BM) B cells, splenic follicular (B220+,
IgM+, IgD+, CD23hi, CD21low), immature (B220+, IgMlow,
IgD-, CD23low, CD21low, CD43+) and marginal B cells
(B220+, IgM+, IgD-, CD23low, CD21hi), peritoneal B1
(CD5+, IgM+) and B2 cells (CD5-, IgM+), splenic mature
T cells (CD4, CD8), thymic immature T cell subsets (CD4,
CD8) and activated B cells (CD69). There was no statisti-
cally significant difference between WT and TG litterma-
tes, with the exception of BM B220dim, CD43+ immature
B cells (WT 22 ± 3% versus TG 15 ± 1%, p = 0.035). CD69
mean fluorescence intensity on BM and spleen B cells was
statistically not significantly different. Histological analy-
sis did not show lymphoid abnormalities. These results
indicate that B cell lymphomas in our model develop
without a prodromic pro-B cell hyperplasia.
Mammary tumor formation upon epithelial 
transplantation
Whole mount analysis of mammary glands taken from
young sexually mature females showed that ductal devel-
opment was complete in both TG and WT animals, with
the ductal tree reaching the confines of the fat pad (Fig.
5A). A similar finding was made by Costa et al. in a related
dominant negative RAR transgenic model [34]. Therefore,
the fact that we did not observed mammary tumor devel-
opment within the time scale shown in Fig. 2A cannot be
attributed to altered ductal development, nor to our
choice of the FVB/N strain since MMTV-driven expression
of "classical" oncogenes and other genes is tumorigenic in
this strain. In several of these models, some or most
tumors do not develop until late in the life of the animal
[35-37]. We therefore wondered whether mammary
tumors might arise in MMTV-RARαG303E mice were it
not for the fact that they succumb to lymphomas first. To
begin to test this idea, we performed an experiment
designed to bypass lymphoma development. We trans-
planted TG mammary epithelium from young disease-
free females to a WT host whose abdominal mammary
glands had been precleared of native epithelium (Fig. 5B).
Sham controls confirmed that the endogenous epithelium
was fully removed. A total of four transplant recipients
were allowed to mate freely and followed over time. Two
mice died disease-free and were lost to follow-up. One of
the transplanted glands in the remaining two subjects
developed a mammary adenocarcinoma with lung metas-
tasis 17 months after transplantation (Fig. 5C). Neither
mouse developed lymphoma. In total, a metastatic mam-
mary carcinoma arose in one of four glands transplanted
with TG epithelium but in none of sixteen host glands
bearing intact WT epithelium. This result was not statisti-
cally significant (chi square), which is hardly surprising
given the very preliminary nature of the study. However,
we were able to document that the mammary carcinoma
was transgenic (Fig. 5C), as expected from the fact that i)
it arose in a gland that received a TG epithelium transplant
and ii) sham controls invariably confirmed that clearing
of endogenous WT epithelium was complete. Thus, there
is virtually no doubt that the mammary epithelium is sus-
ceptible to transformation by RARαG303E. This and the
success of our strategy in bypassing lymphoma develop-
ment suggest that further studies of the susceptibility of
MMTV-RARαG303E mice to mammary tumor formation,
particularly in combination with other transforming
events, is warranted. It will also be worthwhile to test for
evidence of mammary hyperplasia in TG versus WT litter-
mates at an early age, i.e., prior to the time when lympho-
mas begin to appear. As we pursue these studies, it will be
of interest to test whether similar proproliferative and
antiapoptotic strategies underlie dominant negative RAR
transformation of B cells and mammary epithelial cells.
For instance, decreased cyclin D1, cdk4 and cyclin E are
associated with RA mediated G1 arrest [38].
Discussion
Lymphomas in our model were transitional B cell type
because of the presence of markers of immaturity (CD43,
lack of surface Ig, occasional TdT positivity). They also
lacked BCL6, which is otherwise typically present in
human germinal center-derived lymphomas, including
high grade human Burkitt's [39]. We did not find T cell
lymphomas or frank myeloid leukemias. The interesting
finding of a mixed B and myelomonocytic tumor in one
mouse (Results section) suggests origination of the proc-
ess in a progenitor retaining the plasticity to be pro-
grammed in two usually distinct lineages [40].
The growth of lymphomas is typically supported by the
expression of an anti-apoptotic protein [39,41,42]; how-
ever, MMTV-RARαG303E lymphomas did not express
BCL6, BCL2 or MCL1 (Results section), and preliminary
data indicated that BCL-XL is weakly expressed. These
findings suggest that a survival mechanism that is inde-
pendent of these potent inhibitors of apoptosis wards off
cell death in our model.
Despite the fact that they do not overexpress c-MYC pro-
tein, MMTV-RARαG303E lymphomas resembled, histo-
logically and phenotypically, other types of high grade
lymphomas with transitional phenotype, such as the ones
driven by deregulated MYC expression [43-46]. However,
in the latter models, most mice succumb to lymphomas at
14–30 weeks of life whereas in our model morbidity
began later (27 weeks), suggesting a requirement for addi-
tional transforming events. Another difference was the
absence of BM pro-B cell hyperplasia and activation,
noticed in the Eµ-MYC mice [44]. In fact, healthy MMTV-
RARαG303E mice had moderately reduced numbers of
pro-B cells in the bone marrow and lacked CD69.Molecular Cancer 2006, 5:12 http://www.molecular-cancer.com/content/5/1/12
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Interestingly, Manshouri et al. generated RARα antisense
transgenic mice and showed that they develop B and T cell
lymphomas [19]. However, whereas in this model tumor
development was associated with high BCL2 protein
expression [47], our model generated exclusively BCL2
negative B cell lymphomas restricted to a specific window
of differentiation, with a homogeneous transitional phe-
notype, all of high grade. The absence of immunologic
abnormalities preceding the lymphoma onset is also a
unique aspect of our model. These differences may be
explained by differences in experimental design with
respect both to the nature of the transgene (RARαG303E
as opposed to RARα antisense) and the promoter driving
its expression (MMTV-LTR as opposed to the pMAMneo
expression vector which confers wider tissue expression).
Though the evidence is very preliminary at this stage, our
observation that RARαG303E has the potential to trans-
form the mammary epithelium is intriguing. A large scale
version of our pilot study is required to determine the
magnitude of this potential. Wang et al. recently devel-
oped a transgenic model virtually identical to ours
(below) and reported increased mammary branching in
pubertal transgenic females [48], an observation that may
or may not relate to our finding. It is important to note
that our observation of mammary transformation by a
dominant negative RAR is not without precedent. Thus,
early studies by Berard et al. showed that lung and mam-
mary carcinomas develop in MMTV-mRARβ4-like trans-
genic mice [49]. However, whether this can be attributed
to a dominant negative-like activity of mRARβ4 [50]
remains unclear since the transcriptional activity of this
receptor is promoter context- and response element-
dependent [51] and since the altered N-terminus of the
mRARβ4-like transgene could conceivably have intro-
duced an artifact. However, the use of RARαG303E is also
not without caveat; thus, in K14-RARαG303E transgenic
mice, which exhibit a skin phenotype, RARαG303E was
shown to act via a pathway that is independent of DNA
binding [52].
While this manuscript was in preparation, Wang et al.
reported the generation of an apparently identical model
to that we have described here, i.e., transgenic MMTV-
RARαG303E mice in an FVB/N background [53]. Their
mice developed B cell lymphomas with similar kinetics
and the same phenotype as we have reported here. All
seven transgenic founders they obtained developed B cell
lymphoma, thus leaving little doubt that this phenotype
is a result of transgene expression per se and not inser-
tional mutagenesis. Our study and that of Wang et al. pro-
vide mutual and independent confirmation of the
susceptibility of MMTV-RARαG303E mice to the forma-
tion of immature B cell lymphomas. Importantly, their
study showed that RA treatment inhibited lymphoma
growth, an observation that strongly suggests that
RARαG303E acted as a bonafide dominant negative RAR.
Our study extends theirs in several important regards: i)
we demonstrate through extensive analysis that the trans-
gene does not affect pre-tumor lymphoid differentiation
(Results section); ii) we show by immunostaining that the
tumors were positive for Pax-5, which is the most faithful
and restricted (in the hematopoietic system) lymphoid
transcription factor and remarkably evolutionarily con-
served in B cells (Fig. 3); iii) we immunostained tumors
Histological and immunostaining analysis Figure 3
Histological and immunostaining analysis. (A) Low 
power (10x) and high power (40x, inset) image of an H&E 
stained representative case of MMTV-RARαG303E Burkitt's 
lymphoma. (B) The tumor cells stain for PAX-5 (blue). (C) 
BCL6 staining is negative. (D) Low power (10x) and high 
power (40x, inset) image of an H&E stained biphenotypic B-
myelomonocytic tumor. (E, F) Low power (E, 10x) and high 
power (F, 40x) image of Pax-5 (blue) and Mac-2 (red) immu-
nostaining showing separate cell populations (same tumor as 
in D).Molecular Cancer 2006, 5:12 http://www.molecular-cancer.com/content/5/1/12
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for a number of relevant proteins including c-MYC, p53,
BCL6, BCL2 and MCL1 (Fig. 3 and Results section); iv) we
describe an unusual biphenotypic B-myelomonocytic
tumor that implies origination of the transformation
process in a plastic progenitor cell (Fig. 3 and Discussion);
and v) we provide very early but nevertheless intriguing
evidence that RARαG303E can transform the mammary
epithelium (Fig. 5).
Conclusion
Our data suggest that perturbation of physiological RAR
activity has major health consequences. Thus, expression
of a dominant negative RAR in mouse lymphoid tissue
and mammary epithelium resulted in their malignant
transformation. This is of potential clinical significance in
view of the growing body of evidence showing that epige-
netic changes underlie many human malignancies and
specifically that epigenetic silencing of the cellular retinol
binding protein I and RARβ2 are common events in
human lymphoma and breast cancer.
Methods
Generation and maintenance of transgenic mice
All experiments were performed under Institutional Ani-
mal Care and Use Committee approval. RARαG303E was
excised from pCMX-RAR-E [26] as a Hind III-Bam HI frag-
ment and Klenow filled to generate blunt ends. This frag-
ment was subcloned into MMTV-SV40-Bssk [54] digested
with EcoRI and Klenow filled (blunt end ligation). Insert
orientation was determined by DNA sequencing. The
entire MMTV promoter-RARαG303E fragment was
obtained by digestion with Sal I and Spe I (see Fig. 1A).
This fragment was gel eluted and purified by ultracentrif-
ugation through CsCl gradient and turned over to the
Mouse Genetics Shared Research Facility for pronuclear
microinjection (FVB/N background). The data herein was
obtained from the study of a hemizygous line established
from founder 17; founder 24 died of B cell lymphoma and
its tumors were also characterized. Founder 6 transmitted
the transgene to its offspring but a hemizygous line was
not successfully maintained. Founder 39 died of
unknown cause. Line 17 TG males were sterile as judged
by their inability to sire litters after multiple attempts.
Male sterility was previously described and studied in a
related dominant negative RAR model [34] and was like-
wise observed by Wang et al. [48]. MMTV line 17 was
maintained by interbreeding TG females to WT males; the
transgene was transmitted in a Mendelian fashion.
Genotyping and RT-PCR
Tail DNA was digested with KpnI and SacI to release a 503
bp RARαG303E fragment and Southerns probed with
RARαG303E cDNA. Endogenous RARα yielded a ~9 kb
fragment. PCR genotyping as well as RT-PCR took advan-
tage of the HA tag to distinguish the transgene from WT
RARα. For PCR, amplification (25 cycles) was carried out
with forward primer (5'-3') TACCCCTACGACGT-
GCCCGACTATGCCAGC, reverse primer (5'-3') GTTTCT-
CACAGACTCCTTGGACATGCCCAC, and 66°C
Flow cytometric analysis Figure 4
Flow cytometric analysis. (A) One representative tumor and (B) spleen (Spl) or bone marrow (BM) from a healthy litter-
mate were analyzed for surface marker expression. Note, in the tumor, the intermediate expression of B220, the absence of 
surface IgM, IgD and Ig light chains, the coexpression of CD43 and B220 and the positivity for CD69.Molecular Cancer 2006, 5:12 http://www.molecular-cancer.com/content/5/1/12
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annealing temperature. Total RNA was isolated using
either the classical, more stringent Trizol method [55] or
the Purescript kit from Gentra Systems (Minneapolis,
MN). For RT-PCR, 2 µg of total RNA were reverse tran-
scribed using random primers and 1/10th of the cDNA
used as PCR input. Amplification was carried out with the
same primers and conditions as above. Amplification
Mammary epithelial transplantation Figure 5
Mammary epithelial transplantation. (A) Abdominal mammary gland whole mounts showing mature mammary duct 
development in 17-week old TG and WT virgin females. The mammary lymph node, a positional landmark, is partially visible 
(darkly stained body, left end of panel). (B) Diagram illustrating the procedure of mammary epithelial transplantation. Blue 
oval, mammary fat pad; the ductal tree is represented in purple; small black oval, mammary lymph node; tissue to the left of the 
vertical line is surgically removed leaving a cleared fat pad. See Methods for details. (C) Left, H&E stained section of the mam-
mary adenocarcinoma and metastatic lung nodule (inset) that arose after transplantation of TG epithelium into the cleared fat 
pad of a WT host. Tissue was fixed in formalin and embedded in paraffin. Right, DNA was isolated from parallel sections and 
PCR performed, confirming the presence of the transgene in the tumor (M, markers).Molecular Cancer 2006, 5:12 http://www.molecular-cancer.com/content/5/1/12
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reactions in which the RT step was omitted were included
to control for contaminating DNA.
Flow cytometric analysis
Single cell suspensions from normal organs or tumor
mass were stained with the following antibody combina-
tions: A: B220, IgM, IgD, Ig kappa light chain.; B: B220,
CD23, CD21, CD11b.; C: IgM, CD43, CD5, CD19; D:
B220, CD69, CD80.; E: B220, A44.1, IgM, CD43.; F: CD3,
CD4, CD8. All antibodies except for IgD-Pe (Southern
Biotechnology Inc. Birmingham, ALA) were form BD-
Pharmingen (San Diego, CA). A Becton Dickinson FACS
Calibur (BD-Pharmingen) was used for the analysis.
FlowJo 6.1.1 (Tree Star Inc. Ashland, OR) was used for the
analysis and graphic elaboration of the data.
Histology, immunohistochemistry and 
immunofluorescence
Four µm-thick formalin fixed, paraffin embedded sections
were stained for H&E or immunostained as published pre-
viously [56,57]. Briefly, dewaxed, 0.01 mM EDTA antigen-
retrieved sections were blocked in 5% defatted milk pow-
der in TBS-TritonX100, incubated overnight with primary
antibodies against: rabbit anti BCL6, c-MYC, Bcl2, OCT-2,
and IRF4 (Santa Cruz Biotechnology, CA), mouse anti
Pax5, rat anti B220, CD138 (BD-Pharmingen), PNA lectin
(Vector, Burlingame, CA) and rat anti Mac-2 (Cedarlane,
Ontario, Canada), p53 CM5 (Novocastra, Newcastle-U-
Tyne, UK). The specificity and reactivity of these reagents
on mouse tissue was previously defined. Two rabbit anti-
bodies against MCL-1 (S-19, sc-819 from Santa Cruz and
600-401-394 from Rockland, Gilbertsville, PA), generated
against two unrelated epitopes of the molecule, were used
to stain tumor tissue. These antibodies reacted with
mouse normal germinal center and other selected tissues
in an identical manner; the former was used at 0.2 µg/ml
for further characterization of the lymphomas. The pri-
mary antibodies were counterstained with biotin- or Alka-
line Phosphatase (AP) -conjugated secondary antibodies
(Vector or Southern Biotechnology Associates, Birming-
ham, ALA). Biotin-conjugated antibodies received either
Avidin-HRP (DAKOUSA, Carpintera, CA) or Avidin-AP.
The enzymes were developed with AEC (AminoethylCar-
bazole, Sigma) or NBT-BCIP (Roche). Double immuno-
histochemical staining was performed as published
previously [58] with non-crossreacting combinations of
primary and secondary antibodies.
Mammary gland procedures
The technique of mammary epithelial transplantation has
been described in detail [59]. Briefly, a 14-week old
RARαG303E female (donor) and 3 to 4-week old virgin
WT females (recipients) were anesthetized, the abdominal
mammary glands of the donor surgically exposed, and 2
mm3 gland fragments excised and placed on sterile PBS on
ice. The abdominal mammary glands of the recipients
were then surgically exposed and cleared of epithelium by
cauterizing the fat pad at a point distal to the mammary
lymph node (in 3 to 4-week old virgins the ducts lie prox-
imal to the node, Fig. 5B); two donor fragments were
implanted into a pocket prepared in the middle of each
cleared fat pad. Finally, skin flaps were sutured with
wound clips. Sham controls underwent gland clearing
without receiving epithelial implants. Mammary whole
mounts were prepared as described [60].
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